early breast cancer clinical trials results

pertuzumab versus placebo
Aphinity, NCT01358877	versus	people with operable HER2-positive eBC	double-blind
trastuzumab versus control
NSABP B31, 2005	52 weeks of trastuzumab versus no trastuzumab	patients with node-positive, HER2-positive breast cancer
BCIRG006, 2013	versus
Buzdar, 2005	simultaneous weekly trastuzumab for 24 weeks versus no trastuzumab	patienst with HER 2-positive operable breast cancer
FinHer, 2006	concomitant treatment with trastuzumab versus no trastuzumab	Women with tumors that overexpressed HER2/neu
HERA, 2005	??? versus ???	patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy
N9831, 2005	versus
NOAH, 2010	1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment versus no trastuzumab	patients with HER2-positive locally advanced breast cancer
PACS-04, 2009	versus
N9831 (1), 0	versus
N9831 (2), 0	versus
FinHer (1), 3000	versus
HERA (BIG 01-01) 1-year, 2005 NCT00045032	one years of trastuzumab given every three weeks versus observation	patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy	open Follow-up duration: 2 years
NCCTG N9831(C vs A),	same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel versus doxorubicin and cyclophosphamide followed by weekly paclitaxel	Early-stage invasive breast cancer, node positive or high-risk node negative (tumor 1 cm if HR negative or 2 cm if HR positive)	Follow-up duration: 2.9 years
trastuzumab during chemotherapy versus control
NSABP B-31,	same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks	Early-stage, node-positive invasive breast cancer	Follow-up duration: 2.9 years